Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment

International Journal of Oncology

Volumn 43, Issue 5, 2013, Pages 1683-1690

  Maynadier, Marie ^a,c   Farnoud, Reza ^a,c   Lamy, Pierre Jean ^d   Laurent Matha, Valérie ^a,b,c,d   Garcia, Marcel ^a   Rochefort, Henri ^a,b,c,d  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^c INSERM   (France)

^d CENTRE VAL D AURELLE   (France)

Author keywords

Acidic pH; Breast cancer; Cathepsin D; Plasminogen activator

Indexed keywords

AMILORIDE; CATHEPSIN D; PEPSTATIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACIDITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL PH; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOXIA; IMMUNOREACTIVITY; LYSOSOME; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR MICROENVIRONMENT; ZYMOGRAPHY;

BLOTTING, WESTERN; BREAST NEOPLASMS; CATHEPSIN D; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOENZYME TECHNIQUES; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TUMOR CELLS, CULTURED;

EID: 84885074514     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2095     Document Type: Article

References (51)

1. Spyratos F, Brouillet JP, Defrenne A, et al: Cathepsin-D: an independant prognostic factor for metastasis of breast cancer. Lancet 8672: 1115-1118, 1989.
2. Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder M, van Putten WLJ and Klijn JGM: Cathepsin D in primary breast cancer: prognostic evaluation involving 2810 patients. Br J Cancer 79: 300-307, 1999.
3. Rochefort H, Garcia M, Glondu M, Laurent V, Liaudet E, Rey JM and Roger P: Cathepsin D in breast cancer: mechanisms and clinical applications a 1999 overview. Clinica Chimica Acta 291: 157-170, 2000.
4. Capony F, Rougeot C, Montcourier P, Cavaillès V, Salazar G and Rochefort H: Increased secretion altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. Cancer Res 49: 3904-3909, 1989.
5. Rochefort H, Capony F and Garcia M: Cathepsin D: a protease involved in breast cancer metastasis. Cancer Metastasis Rev 9: 321-331, 1990.
6. Veith FO, Capony F, Garcia M, Chantelard J, Pujol H, Veith F, Zajdela A and Rochefort H: Release of estrogen-induced glycoprotein with a molecular weight of 52,000 by breast cancer cells in primary culture. Cancer Res 43: 1861-1868, 1983.
7. Stubbs M, McSheehy PM and Griffiths JR: Causes and consequences of acidic pH in tumors: a magnetic resonance study. Adv Enzyme Regul 39: 13-30, 1999.
8. Martin GR and Jain RK: Measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy. Cancer Res 54: 5670-5674, 1994.
9. Foekens JA, Peters HA, Look MP, et al: The urokinase system of plasminogen activation and prognosis in 2,780 breast cancer patients. Cancer Res 60: 636-643, 2000.
10. Harbeck N, Schmitt M, Meisner C, et al: Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 49: 1825-1835, 2013.
11. Heuser J: Changes in lysosome shape and distribution correlated with changes in cytoplasmic pH. J Cell Biol 108: 855-864, 1989.
12. Montcourrier P, Silver IA, Farnoud R, Bird I and Rochefort H: Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis 15: 382-392, 1997.
13. Chalbos D, Vignon F, Keydar I and Rochefort H: Estrogens stimulate cell proliferation and induce secretory proteins in a human breast cancer cell line (T47D). J Clin Endocrin Metab 55: 276-283, 1982.
14. Martínez-Zaguilán R, Seftor EA, Seftor RE, Chu YW, Gillies RJ and Hendrix MJ: Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14: 176-186, 1996.
15. Heussen C and Dowdle EB: Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102: 196-202, 1980.
16. Vassalli JD and Belin D: Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett 214: 187-191, 1987.
17. Maynadier M, Ramirez JM, Cathiard AM, et al: Unliganded estrogen receptor alpha inhibits breast cancer cell growth through interaction with a cyclin-dependent kinase inhibitor (p21(WAF1)). FASEB J 22: 671-681, 2008.
18. Garcia M, Capony F, Derocq D, Simon D, Pau B and Rochefort H: Characterization of monoclonal antibodies to the estrogen-regulated Mr 52,000 glycoprotein and their use in MCF7 cells. Cancer Res 45: 709-716, 1985.
19. Brouillet JP, Spyratos F, Hacene K, Fauque J, Freiss G, Dupont F, Maudelonde T, Rochefort H: Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D. Eur J Cancer 29A: 1248-1251, 1993.
20. Tissot JD, Hauert J and Bachmann F: Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer 34: 295-302, 1984.
21. Christensen L, Wiborg Simonsen AC, Heegaard CW, Moestrup SK, Andersen JA and Andreasen PA: Immuno-histochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and α2-macroglobulin receptor in human breast carcinomas. Int J Cancer 66: 441-452, 1996.
22. Jankun J and Skrzypczak-Jankun E: Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. Cancer Biochem Biophys 17: 109-123, 1999.
23. Simon DI, Xu H and Vaughan DE: Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes. Biochim Biophys Acta 1268: 143-145, 1995.
24. Rochefort H and Liaudet-Coopman E: Cathepsin D in cancer metastasis: a protease and a ligand. Acta Pathol Microb Immunol Scand 107: 86-95, 1999.
25. Rofstad K, Mathiesen B, Kindem K and Galappathi K: Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 66: 6699-6707, 2006.
26. Ryan TJ, Seeger JI, Kumar SA and Dickerman HW: Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells. J Biol Chem 259: 14324-14327, 1984.
27. Jessani N, Humphrey M, McDonald WH, et al: Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo. Proc Natl Acad Sci USA 101: 13756-13761, 2004.
28. Briozzo P, Badet J, Capony F, Pieri I, Montcourrier P, Barritault D and Rochefort H: MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res 194: 252-259, 1991.
29. Liaudet E, Garcia M and Rochefort H: Cathepsin D maturation and its stimulatory effect on metastasis are prevented by addition of KDEL retention signal. Oncogene 9: 1145-1154, 1994.
30. Richo G and Conner GE: Proteolytic activation of human procathepsin D. Adv Exp Med Biol 306: 289-296, 1991.
31. Rozhin J, Sameni M, Ziegler G and Sloane BF: Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54: 6517-6525, 1994.
32. Tate KM, Higgins DL, Holmes WE, Winkler ME, Heyneker HL and Vehar GA: Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 26: 338-343, 1987.
33. Berg DT and Grinnell BW: Signal and propeptide processing of human tissue plasminogen activator: activity of a pro-tPA derivative. Biochem Biophys Res Commun 179: 1289-1296, 1991.
34. Cajot JF, Kruithof EK, Schleuning WD, Sordat B and Bachmann F: Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer 38: 719-727, 1986.
35. Suzuki Y, Mogami H, Ihara H and Urano T: Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells. Blood 113: 470-478, 2009.
36. Rijken DC, Hoegee-de Nobel E, Jie AF, Atsma DE, Schalij MJ and Nieuwenhuizen W: Development of a new test for the global fibrinolytic capacity in whole blood. J Thromb Haemost 6: 151-157, 2008.
37. Sharma M, Ownbey RT and Sharma MC: Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation. Exp Mol Pathol 88: 278-286, 2010.
38. Krieger M and Herz J: Structures and functions of multi-ligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 63: 601-637, 1994.
39. Beaujouin M, Prébois C, Derocq D, et al: Pro-cathepsin D interacts with the extracellular domain of the beta chain of LRP1 and promotes LRP1-dependent fibroblast outgrowth. J Cell Sci 123: 3336-3346, 2010.
40. Mason SD and Joyce JA: Proteolytic networks in cancer. Trends Cell Biol 4: 228-237, 2011.
41. Pagano M, Capony F and Rochefort H: Pro-cathepsin D can activate in vitro pro-cathepsin B secreted by ovarian cancers. C R Acad Sci III. 309: 7-12, 1989 (In French).
42. Nishimura Y, Kawabata T, Furuno K and Kato K: Evidence that aspartic proteinase is involved in the proteolytic processing event of procathepsin L in lysosomes. Arch Biochem Biophys 271: 400-406, 1989.
43. Danø K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M and Romer J: Plasminogen activation and cancer. Thromb Haemost 93: 676-681, 2005.
44. Fredriksson L, Li H, Fieber C, Li X and Eriksson U: Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 23: 3793, 2004.
45. Seeds NW, Basham ME and Haffke SP: Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc Natl Acad Sci USA 96: 14118-14123, 1999.
46. Carmeliet P, Schoonjans L, Kieckens L, et al: Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424, 1994.
47. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HR: Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 48: 1348-1349, 1988.
48. Chappuis P O, Dieterich B, Sciretta V, Lohse C, Bonnefoi H, Remadi S, and Sappino AP: Functional evaluation of plasmin formation in primary breast cancer J Clin Oncol 19: 2731-2738, 2001.
49. Kortlever RM, Higgins PJ and Bernards R: Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nature Cell Biol 8: 877-884, 2006.
50. Conover CA and De Leon DD: Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin D. J Biol Chem 269: 7076-7080, 1994.
51. Elzi DJ, Lai Y, Song M, Hakala K, Weintraub ST and Shiio Y: Plasminogen activator inhibitor 1-insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence. Proc Natl Acad Sci USA 109: 12052-12057, 2012.